Skip to main content
Article thumbnail
Location of Repository

The Interaction between Early Life Epilepsy and Autistic-Like Behavioral Consequences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway

By Delia M. Talos, Hongyu Sun, Xiangping Zhou, Erin C. Fitzgerald, Michele C. Jackson, Peter M. Klein, Victor J. Lan, Annelise Joseph and Frances E. Jensen


Early life seizures can result in chronic epilepsy, cognitive deficits and behavioral changes such as autism, and conversely epilepsy is common in autistic children. We hypothesized that during early brain development, seizures could alter regulators of synaptic development and underlie the interaction between epilepsy and autism. The mammalian Target of Rapamycin (mTOR) modulates protein translation and is dysregulated in Tuberous Sclerosis Complex, a disorder characterized by epilepsy and autism. We used a rodent model of acute hypoxia-induced neonatal seizures that results in long term increases in neuronal excitability, seizure susceptibility, and spontaneous seizures, to determine how seizures alter mTOR Complex 1 (mTORC1) signaling. We hypothesized that seizures occurring at a developmental stage coinciding with a critical period of synaptogenesis will activate mTORC1, contributing to epileptic networks and autistic-like behavior in later life. Here we show that in the rat, baseline mTORC1 activation peaks during the first three postnatal weeks, and induction of seizures at postnatal day 10 results in further transient activation of its downstream targets phospho-4E-BP1 (Thr37/46), phospho-p70S6K (Thr389) and phospho-S6 (Ser235/236), as well as rapid induction of activity-dependent upstream signaling molecules, including BDNF, phospho-Akt (Thr308) and phospho-ERK (Thr202/Tyr204). Furthermore, treatment with the mTORC1 inhibitor rapamycin immediately before and after seizures reversed early increases in glutamatergic neurotransmission and seizure susceptibility and attenuated later life epilepsy and autistic-like behavior. Together, these findings suggest that in the developing brain the mTORC1 signaling pathway is involved in epileptogenesis and altered social behavior, and that it may be a target for development of novel therapies that eliminate the progressive effects of neonatal seizures

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). 7-12 Hz high-voltage rhythmic spike discharges in rats evaluated by antiepileptic drugs and flicker stimulation.
  2. (2007). A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival.
  3. (2011). A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
  4. (2002). A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus.
  5. (2011). Absence of preference for social novelty and increased grooming in integrin beta3 knockout mice: initial studies and future directions.
  6. (2006). Activity bidirectionally regulates AMPA receptor mRNA abundance in dendrites of hippocampal neurons.
  7. (2004). Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.
  8. (2002). Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures.
  9. (2010). Autism and epilepsy: historical perspective.
  10. (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.
  11. (2009). BDNF activates mTOR to regulate GluR1 expression required for memory formation.
  12. (2006). BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan.
  13. (1991). BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF.
  14. (2010). Behavioural phenotyping assays for mouse models of autism.
  15. (2010). Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.
  16. (2007). Biphasic ERK1/ 2 activation in both the hippocampus and amygdala may reveal a system consolidation of contextual fear memory.
  17. (2004). Brainderived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites.
  18. (2001). Calcium regulation of neuronal gene expression.
  19. (2011). Chronic electrographic seizure reduces glutamine and elevates glutamate in the extracellular fluid of rat brain.
  20. (2007). Cognitive prognosis of patients with tuberous sclerosis complex.
  21. Crino PB (2010) The tuberous sclerosis complex.
  22. (2011). Development of later life spontaneous seizures in a rodent model of hypoxiainduced neonatal seizures.
  23. (2006). Developmental regualtion of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex.
  24. (2006). Developmental regualtion of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex.
  25. (2010). Dysregulation of mTOR signaling in fragile X syndrome.
  26. (2008). Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures.
  27. (2007). Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons.
  28. (2010). Epilepsy and autism spectrum disorders: are there common developmental mechanisms?
  29. (2011). Epilepsy and autism: neurodevelopmental perspective.
  30. (2011). Epilepsy as a spectrum disorder: Implications from novel clinical and basic neuroscience.
  31. (2008). Epilepsy surveillance among adults–19 States, Behavioral Risk Factor Surveillance System,
  32. (2007). Epilepsy: being ill in more ways than one.
  33. (2009). Epileptogenesis in the immature brain: emerging mechanisms.
  34. (2010). Extracellular signal-regulated kinase 1/2 (ERK1/2) activated in the hippocampal CA1 neurons is critical for retrieval of auditory trace fear memory.
  35. (2011). Fragile X mental retardation protein regulates heterosynaptic plasticity in the hippocampus.
  36. (2009). From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.
  37. (2010). GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism.
  38. (2008). Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.
  39. (2011). Hypoxia-induced neonatal seizures diminish silent synapses and long-term potentiation in hippocampal CA1 neurons.
  40. (2012). Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin.
  41. (2011). Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County,
  42. (2009). Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy.
  43. (2005). Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway.
  44. (2005). Long-term effects of acute and of chronic hypoxia on behavior and on hippocampal histology in the developing brain.
  45. (2007). Long-term prognosis in children with neonatal seizures: a population-based study.
  46. (2009). Making synaptic plasticity and memory last: mechanisms of translational regulation.
  47. (2010). Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
  48. (2007). Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of rapamycin pathway.
  49. (2009). Molecular mechanisms of mTOR-mediated translational control.
  50. (2007). Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains.
  51. (2010). mTOR phosphorylated at S2448 binds to raptor and rictor.
  52. (2010). mTOR signaling: at the crossroads of plasticity, memory and disease.
  53. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing.
  54. (1995). NBQX blocks the acute and late epileptogenic effects of perinatal hypoxia.
  55. (2004). NBQX or topiramate treatment following perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury.
  56. (1999). Neuroprotective effects of brain-derived neurotrophic factor in seizures during development.
  57. (2009). New insights into the role of brain-derived neurotrophic factor in synaptic plasticity.
  58. (2012). Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.
  59. (2007). Persistence of long-term memory storage requires a late protein synthesisand BDNF- dependent phase in the hippocampus.
  60. (2009). Persistent transcription- and translation-dependent long-term potentiation induced by mGluR1 in hippocampal interneurons.
  61. (2010). Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.
  62. (2002). Pickles A
  63. (2010). Psychiatric comorbidity in patients with epilepsy: a population-based study.
  64. (2006). Pten regulates neuronal arborization and social interaction in mice.
  65. (2008). Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
  66. (2011). Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy.
  67. (2011). Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.
  68. (2005). Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways.
  69. (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
  70. (2005). Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2.
  71. (2010). Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.
  72. (2008). Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
  73. (2008). Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.
  74. (1994). rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Rasrelated protein.
  75. (2008). Role of mTOR in physiology and pathology of the nervous system.
  76. (2004). S6K1(-/-)/ S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 59-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.
  77. (2004). Sociability and preference for social novelty in five inbred strains: an approach to assess autisticlike behavior in mice.
  78. (2008). Social approach and repetitive behavior in eleven inbred mouse strains.
  79. (2006). Stress and mTORture signaling.
  80. (2006). The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants.
  81. (1975). The epidemiology of epilepsy in
  82. (2006). The growing role of mTOR in neuronal development and plasticity.
  83. (2008). The immediate early gene arc/arg3.1: regulation, mechanisms, and function.
  84. (2009). The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.
  85. (2011). The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Current cancer drug targets 11:
  86. (2009). The role of epilepsy and epileptiform EEGs in autism spectrum disorders.
  87. (2003). Timerestricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1.
  88. (2004). Translational Regulatory Mechanisms in Persistent Forms of Synaptic Plasticity.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.